Cargando…
Perinatal use of triptans and other drugs for migraine—A nationwide drug utilization study
OBJECTIVE: To characterize nationwide utilization patterns of migraine pharmacotherapy before, during, and after pregnancy in women with triptan use. METHODS: Population-based data were obtained by linking the Medical Birth Registry of Norway and the Norwegian Prescription Database from 2006 to 2017...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382165/ https://www.ncbi.nlm.nih.gov/pubmed/34424941 http://dx.doi.org/10.1371/journal.pone.0256214 |
_version_ | 1783741497541132288 |
---|---|
author | Tauqeer, Fatima Wood, Mollie Hjorth, Sarah Lupattelli, Angela Nordeng, Hedvig |
author_facet | Tauqeer, Fatima Wood, Mollie Hjorth, Sarah Lupattelli, Angela Nordeng, Hedvig |
author_sort | Tauqeer, Fatima |
collection | PubMed |
description | OBJECTIVE: To characterize nationwide utilization patterns of migraine pharmacotherapy before, during, and after pregnancy in women with triptan use. METHODS: Population-based data were obtained by linking the Medical Birth Registry of Norway and the Norwegian Prescription Database from 2006 to 2017. We included 22,940 pregnancies among 19,669 women with at least one filled triptan prescription, a proxy for migraine, in the year before pregnancy or during pregnancy. The population was classified into four groups: i) continuers; ii) discontinuers; iii) initiators, and vi) post-partum re-initiators. Participant characteristics and prescription fills for other drugs such as analgesics, antinauseants, and preventive drugs among the groups were examined, along with an array of triptan utilization parameters. RESULTS: In total, 20.0% of the women were classified as triptan continuers, 54.1% as discontinuers, 8.0% as initiators, and 17.6% as re-initiators. Extended use of triptans (≥15 daily drug doses/month) occurred among 6.9% of the continuers in the first trimester. The top 10% of triptan continuers and initiators accounted for 41% (95% CI: 39.2% - 42.5%) and 33% (95% CI: 30.3% - 35.8%) of the triptan volume, respectively. Triptan continuers and initiators had similar patterns of acute co-medication during pregnancy, but use of preventive drugs was more common among the continuers before, during, and after pregnancy. CONCLUSION: Among women using triptans before and during pregnancy, one in four continued triptan treatment during pregnancy, and extended triptan use was relatively low. Triptan discontinuation during and in the year after pregnancy was common. Use of other acute migraine treatments was higher among both continuers and initiators of triptans. Women using preventive migraine treatment were most commonly triptan continuers and re-initiators after pregnancy. Prescribing to and counseling of women with migraine should be tailored to the condition severity and their information needs to promote optimal migraine management in pregnancy. |
format | Online Article Text |
id | pubmed-8382165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-83821652021-08-24 Perinatal use of triptans and other drugs for migraine—A nationwide drug utilization study Tauqeer, Fatima Wood, Mollie Hjorth, Sarah Lupattelli, Angela Nordeng, Hedvig PLoS One Research Article OBJECTIVE: To characterize nationwide utilization patterns of migraine pharmacotherapy before, during, and after pregnancy in women with triptan use. METHODS: Population-based data were obtained by linking the Medical Birth Registry of Norway and the Norwegian Prescription Database from 2006 to 2017. We included 22,940 pregnancies among 19,669 women with at least one filled triptan prescription, a proxy for migraine, in the year before pregnancy or during pregnancy. The population was classified into four groups: i) continuers; ii) discontinuers; iii) initiators, and vi) post-partum re-initiators. Participant characteristics and prescription fills for other drugs such as analgesics, antinauseants, and preventive drugs among the groups were examined, along with an array of triptan utilization parameters. RESULTS: In total, 20.0% of the women were classified as triptan continuers, 54.1% as discontinuers, 8.0% as initiators, and 17.6% as re-initiators. Extended use of triptans (≥15 daily drug doses/month) occurred among 6.9% of the continuers in the first trimester. The top 10% of triptan continuers and initiators accounted for 41% (95% CI: 39.2% - 42.5%) and 33% (95% CI: 30.3% - 35.8%) of the triptan volume, respectively. Triptan continuers and initiators had similar patterns of acute co-medication during pregnancy, but use of preventive drugs was more common among the continuers before, during, and after pregnancy. CONCLUSION: Among women using triptans before and during pregnancy, one in four continued triptan treatment during pregnancy, and extended triptan use was relatively low. Triptan discontinuation during and in the year after pregnancy was common. Use of other acute migraine treatments was higher among both continuers and initiators of triptans. Women using preventive migraine treatment were most commonly triptan continuers and re-initiators after pregnancy. Prescribing to and counseling of women with migraine should be tailored to the condition severity and their information needs to promote optimal migraine management in pregnancy. Public Library of Science 2021-08-23 /pmc/articles/PMC8382165/ /pubmed/34424941 http://dx.doi.org/10.1371/journal.pone.0256214 Text en © 2021 Tauqeer et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Tauqeer, Fatima Wood, Mollie Hjorth, Sarah Lupattelli, Angela Nordeng, Hedvig Perinatal use of triptans and other drugs for migraine—A nationwide drug utilization study |
title | Perinatal use of triptans and other drugs for migraine—A nationwide drug utilization study |
title_full | Perinatal use of triptans and other drugs for migraine—A nationwide drug utilization study |
title_fullStr | Perinatal use of triptans and other drugs for migraine—A nationwide drug utilization study |
title_full_unstemmed | Perinatal use of triptans and other drugs for migraine—A nationwide drug utilization study |
title_short | Perinatal use of triptans and other drugs for migraine—A nationwide drug utilization study |
title_sort | perinatal use of triptans and other drugs for migraine—a nationwide drug utilization study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382165/ https://www.ncbi.nlm.nih.gov/pubmed/34424941 http://dx.doi.org/10.1371/journal.pone.0256214 |
work_keys_str_mv | AT tauqeerfatima perinataluseoftriptansandotherdrugsformigraineanationwidedrugutilizationstudy AT woodmollie perinataluseoftriptansandotherdrugsformigraineanationwidedrugutilizationstudy AT hjorthsarah perinataluseoftriptansandotherdrugsformigraineanationwidedrugutilizationstudy AT lupattelliangela perinataluseoftriptansandotherdrugsformigraineanationwidedrugutilizationstudy AT nordenghedvig perinataluseoftriptansandotherdrugsformigraineanationwidedrugutilizationstudy |